Physician profile
Oliver M Burrows
NPI 1033157979
$6,264.17
in general payments reported to CMS, 2019-2025
36 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $955 · 2021: $1,313 · 2022: $663 · 2023: $766 · 2024: $758 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $822.34 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $590.07 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $518.95 | 2019-2025 | Airsupra, Breztri |
| Amarin Pharma, INC. | $512.69 | 2019-2021 | |
| Pfizer INC. | $439.59 | 2019-2025 | |
| Amgen INC. | $386.39 | 2019-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $382.29 | 2019-2024 | Xarelto |
| Abbvie INC. | $320.53 | 2019-2023 | Synthroid |
| Takeda Pharmaceuticals U.S.A., INC. | $270.82 | 2019-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $260.99 | 2021-2025 | Zoryve |
| Allergan, INC. | $230.67 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $157.45 | 2021 | |
| Novo Nordisk INC | $113.87 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.09 | 2020-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $96.10 | 2019-2023 | Trelegy Ellipta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $92.16 | 2023-2024 | Strensiq |
| Novartis Pharmaceuticals Corporation | $91.12 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $89.25 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $77.08 | 2023 | Gemtesa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.14 | 2025 | Lifevest |
| Exact Sciences Corporation | $68.84 | 2023-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $64.74 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $63.91 | 2022-2023 | Quviviq |
| Vertiflex, INC. | $47.94 | 2019 | |
| Astellas Pharma US INC | $44.44 | 2019 | |
| Sanofi Pasteur INC. | $43.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.24 | 2019-2020 | |
| Esperion Therapeutics, INC. | $37.44 | 2021 | |
| Abbott Laboratories | $36.46 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.27 | 2019-2025 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $33.80 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.37 | 2023 | Jynarque |
| Almatica Pharma LLC | $24.42 | 2024 | Loreev Xr |
| Dermira, INC. | $24.16 | 2020 | |
| Antares Pharma, INC. | $19.24 | 2019 | |
| Eisai INC. | $18.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.